Background
There is increasing awareness that inflammation may play a role in various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, HIV-associated dementia, trauma, multiple sclerosis and stroke [
1,
2]. Microglial cells are generally considered to be the immune cells of the central nervous system (CNS). They respond to neuronal injury or immunologic challenges with a reaction termed microglial activation. Activated microglial cells can serve diverse beneficial functions essential to neuron survival, which include cellular maintenance and innate immunity [
3,
4]. However, overactivated microglia can induce significant and highly detrimental neurotoxic effects through excess production of a large array of cytotoxic factors such as superoxide, nitric oxide (NO), tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) [
1]. Overactivation of microglia followed by overproduction of neurotoxic factors results in deleterious and progressive neurotoxic consequences [
5,
6]. In several studies it has been shown that reduction of pro-inflammatory mediators produced by microglia may attenuate the severity of neuronal damage [
7]. Therefore, inhibiting inflammatory cytokine production by activated microglia may be useful for preventing neurodegeneration [
8‐
10].
Lipoxins (LXs) are endogenous lipid mediators with potent anti-infiammatory and pro-resolving actions [
11]. Of special interest, aspirin can also trigger transcellular biosynthesis of 15-epimers of LX, termed aspirin-triggered LX (ATL) [
12], that share the potent anti-infiammatory actions of LX but are more resistant to metabolic inactivation [
13]. LXs and ATL elicit multicellular responses via a specific G protein-coupled receptor termed the LXA
4 receptor (ALX) that has been identified in human [
14], mouse [
15] and rat [
16] tissues. In our previous papers, we evaluated the anti-inflammatory activity of an LXA
4 analogue, 5(S), 6(R)-LXA
4 methyl ester, in a rat model of permanent focal cerebral ischemia and focal cerebral ischemia reperfusion [
17,
18]. Our results showed that this LXA
4 analogue could attenuate focal ischemia-induced inflammatory responses and inhibit activation of microglia
in vivo. Expression of functional ALXs was identified in neural stem cells, neurons, astrocytes and microglia [
19‐
23]. Microglial cells are key sensors and versatile effectors in normal and pathologic brain [
24]. These findings suggest that microglia may be a target for LXs in brain. However, the effects of LXs on expression of inflammation-related genes and molecular mechanisms in microglia have not been demonstrated.
Lipopolysaccharide (LPS), a component of the outer membrane of Gram-negative bacteria, initiates a number of major cellular responses that play critical roles in the pathogenesis of inflammatory responses and has been commonly used to model proinflammatory and neurotoxic activation of microglia [
25,
26]. We used LPS as a stimulant of the microglial reactivity in the current study.
In the present study, we investigated the impact of ATL on the infiammatory response induced by LPS in murine microglial BV-2 cells, as well as the signaling pathways involved in these processes. Our data suggest that ATL inhibits NO and pro-inflammatory cytokine production in LPS-activated microglia at least in part via NF-κB, ERK, p38 MAPK and AP-1 signaling pathways.
Methods
Cell culture
The immortalized murine microglia cell line BV-2 was purchased from Cell Resource Centre of Peking Union Medical College (Beijing, China) and maintained in Dulbecco's modified Eagle's medium with F12 supplement (DMEM/F12, Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (Gibco), 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C in a humidified atmosphere of 95% air, 5% CO2. Confiuent cultures were passaged by trypsinization. BV-2 cells were seeded onto 96-well plates (104 cells/well for cell viability assay), 24-well-culture plates (105 cells/well for ELISA and NO measurement, 104 cells/well for immunofluorescence), 6-well plates (2.5 × 105 cells/well for PCR) or 100 mm culture dishes (1.2 × 106 cells/dish for western blotting and EMSA). Before each experiment, cells were serum-starved for 12 h. BV-2 cells were incubated in the initial experiments with different concentrations (1 nM, 10 nM or 100 nM) of ATL (Cayman Chemical, Ann Arbor, MI), leading to a concentration of 100 nM ATL used in further experiments or vehicle (0.035% ethanol) for 30 min before addition of 100 ng/ml LPS (Escherichia coli O26:B6, Sigma-Aldrich, St. Louis, MO) under serum-free conditions. To investigate the involvement of ALXs in the anti-inflammatory effects of ATL, the cells were treated with 100 μM Boc-2 (Phoenix Pharmaceuticals), a specific receptor antagonist, prior to the treatment with ATL for 30 min.
RNA isolation, reverse-transcriptase (RT) PCR and real-time PCR
Total RNA was extracted from BV-2 cells with TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. 1.0 μg of total RNA was subjected to oligo-dT-primed RT with ReverTra Ace Kit (Toyobo, Osaka, Japan).
Semi-quantitative PCR was carried out with DNA polymerase (Toyobo) by using specific primers (Invitrogen): 5'-GGCAACTCTGTTGAGGAAAG-3' and 5'-GGCTCTCGGTAGACGAGA-3', which amplify the 423 bp product for ALX1/FPR-rs1; and 5'-GTCAAGATCAACAGAAGAAACC-3' and 5'-GGGCTCTCTCAAGACTATAAGG-3', which amplify 298 bp product for ALX2/FPR2; and 5'-TGGAATCCTGTGGCATCCATGAAAC-3' and 5'-TAAAACGCAGCTCAGTAACAGTCCG-3', which amplify 349 bp product for β-actin. The amplified PCR products were resolved by 2% agarose gel electrophoresis.
Real-time PCR was performed for a quantitative analysis of iNOS, IL-1β and TNF-α mRNA expression using SYBR Green real-time PCR Master Mix (Toyobo) on an MX3000P real-time PCR system (Stratagene). The following primers were used (Invitrogen): 5'-CAGCTGGGCTGTACAAACCTT-3' and 5'- CATTGGAAGTGAAGCGTTTCG-3', which amplify the 95 bp product for iNOS; 5'-CAACCAACAAGTGATATTCTCCATG-3' and 5'- GATCCACACTCTCCAGCTGCA-3', which amplify the 152 bp product for IL-1β; 5'-CATCTTCTCAAAATTCGAGTGACAA-3' and 5'-TGGGAGTAGACAAGGTACAACCC-3', which amplify the 175 bp product for TNF-α; and 5'-TGTCCACCTTCCAGCAGATGT-3' and 5'-AGCTCAGTAACAGTCCGCCTAGA-3', which amplify the 101 bp product for β-actin. Relative gene expression was calculated by the 2
-ΔΔCT method [
27].
Cell viability assay
Cell viability was measured by quantitative colorimetric assay with MTT (Sigma-Aldrich), showing the mitochondrial activity of living cells. BV-2 cells in 96-well plates were pretreated with various concentrations of ATL for 30 min and incubated with or without LPS for 24 h in the continued presence of ATL. Upon termination of the experiments, the culture media were aspirated and MTT (0.5 mg/ml) was added to cells and then incubated at 37°C for 4 h. The supernatant was aspirated and dimethyl sulfoxide (Sigma-Aldrich) was added to the wells. Insoluble crystals were dissolved by mixing and the plates were read on an automated Tecan Sunrise absorbance reader, using a test wavelength of 570 nm and a reference wavelength of 630 nm.
Nitrite measurements
Production of NO was determined by measuring the level of accumulated nitrite, a metabolite of NO in the culture supernatant using Griess reagent (Sigma-Aldrich). After 24 h of treatment with LPS with or without ATL, the culture supernatants were collected and mixed with an equal volume of Griess reagent in 96-well culture plates and incubated at room temperature for 10 min. The absorbance was measured at 540 nm and nitrite concentrations were calculated by reference to a standard curve generated by known concentrations of sodium nitrite.
ELISA for IL-1β and TNF-α
BV-2 cells in 24-well plates were stimulated for 24 h, and then culture supernatants were harvested. Levels of IL-1β and TNF-α in 100 μl medium were measured by commercial ELISA kits (Boster Biological Technology, Wuhan, China) according to the manufacturer's instructions.
Immunofluorescence confocal microscopy
For the detection of intracellular location of NF-κB p65, BV-2 cells were cultured on sterile glass cover slips in 24 well plates and treated with ATL and LPS as described above. At various times after the LPS treatment, cells were fixed with 4% paraformaldehyde in PBS and permeabilized with 0.1% Triton X-100 in PBS. After rinsing, cells were blocked with 3% BSA in PBS for 1 h and incubated with rabbit anti-NF-κB p65 antibodies (1:200, Santa Cruz Biotechnology, Santa Cruz) overnight at 4°C. After washing, cells were incubated with FITC-conjugated goat anti-rabbit IgG (1:400, Pierce, Rockford, IL) for 1 h and counterstained with 4, 6-diamidino-2-phenylindole (DAPI, Roche, Shanghai, China) for the identification of nuclei. After washing with PBS, the cover slips were mounted with antifade mounting medium (Beyotime, China) on slides, and the cells were observed with a confocal microscope Olympus Fluoview FV500.
For making whole cell lysates, the cells were lysed in radioimmune precipitation assay (RIPA) buffer supplemented with protease inhibitor cocktail (Roche). Nuclear and cytoplasmic fractionations were performed with Proteo JET™ Cytoplasmic and Nuclear Protein Extraction Kit (Fermentas Life Science) according to manufacturer's protocol.
Western blot analysis
Equal amounts of cytoplasmic, nuclear, or whole cell extracts were electrophoresed on sodium dodecyl sulfate-polyacrylamide gels, and then transferred onto a polyvinylidene difluoride membrane (Millipore). The transformed membrane was blocked for 1 h and incubated with indicated primary antibodies (Santa Cruz Biotechnology) at 4°C overnight. The primary antibodies usedwere as follows: rabbit anti-iNOS (1:500), β-actin (1:1000), p65 (1:1000), Lamin B (1:1000), IκB-α (1:500), ERK1/2 (1:1000), p38 (1:1000), JNK (1:1000) and mouse anti-phosphorylated ERK1/2, p38, JNK antibody (1:1000). The membrane was washed three times with Tris-bufffered saline containing 0.05% Tween 20 (TBST) for 10 min and incubated with anti-rabbit or anti-mouse IgG-horseradish peroxidase (1:5000, Pierce) at room temperature for 1 h. The Supersignal West Pico chemiluminescent substrate system (Pierce) was used to detect immunoreactive bands. The intensity of protein bands after western blotting were quantitated by using Quantity One Version 4.6.3 Image software (Bio-Rad) and normalized against proper loading controls.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described above. Oligonucleotides corresponding to the NF-κB (5'-AGTTGAGGGGACTTTCCCAGGC-3') and AP-1 (5'-CGCTTGATGAGTCAGCCGGAA-3') binding site consensus sequences were synthesized and end-labeled with biotin by Invitrogen. EMSAs were performed using the LightShift chemiluminescent EMSA kit (Pierce). Briefly, 20 fmol of biotin-labeled, double strand probe was incubated for 20 min at room temperature in 20 μl of EMSA binding buffer containing 2.5% glycerol, 5 mM MgCl2, 50 ng/μl poly (dI-dC), 0.05% Nonidet P-40, and 6 μg of nuclear proteins. For competition EMSA, 200-fold (4 pmol) excess unlabeled, double strand probe was added to the binding reaction. The DNA-nuclear protein complexes were resolved by electrophoresis in 6% nondenaturing polyacrylamide gel in 0.5 × Tris-borate-EDTA (TBE) buffer at 100 V. Gels were then electroblotted onto Hybond nylon membranes (GE Healthcare) at 380 mA for 50 min. The membranes were then cross-linked for 15 min with the membrane face down on a transilluminator at 312 nm, and the biotinylated protein-DNA bands were detected with HRP-conjugated streptavidin using the chemiluminescent nucleic acid detection system (Pierce).
Statistical analysis
Data are expressed as means ± SEM of the indicated number of independent experiments. Changes in IκB protein levels were analyzed by two-way ANOVA (treatment and time). All other data were analyzed by one-way ANOVA. Least significant difference (LSD) post hoc test was used for multiple comparisons. Statistical analysis was performed using the SPSS software version 17.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered statistically significant.
Discussion
Our present data provide the first evidence that ATL inhibits the infiammatory activation of microglia. To date, two separate LXA
4 receptors (ALX1/FPR-rs1 and ALX2/FPR2) have been identified in mice [
15,
29]. Mouse ALX2/FPR2 is expressed by neutrophils, monocytes, macrophages, dendritic cells, and microglial cells, and its transcripts are detected at high levels in spleen and lung [
30]. ALX1/FPR-rs1 and ALX2/FPR2 are both expressed in the mouse pituitary gland, hypothalamic tissue and vomeronasal organ [
31,
32]. As demonstrated by RT-PCR analysis, ALX1/FPR-rs1 and ALX2/FPR2 are both expressed in BV-2 microglial cells. ATL reduced LPS-induced production of NO, IL-1β and TNF-α in BV-2 microglial cells. This is a receptor-mediated effect as it disappeared when microglial cells were pretreated with Boc-2 before ATL treatment. Quantitative PCR analysis showed that ATL markedly suppresses iNOS, IL-1β and TNF-α gene expression in BV-2 microglia cells. Similarly, this effect was abrogated by the use of Boc-2. NF-κB, ERK and p38 MAPK pathways are at least partly involved in the anti-infiammatory mechanisms of ATL in BV-2 cells. Thus, ATL is a promising agent for preventing and treating neuroinflammation and may be useful for mitigating a dysregulated linkage between the immune system and brain.
Although microglial activation has important repairative functions in the CNS, microglial cell activation in infection, infiammation, or injury may go beyond control and eventually produce detrimental effects that override the beneficial effects. Activation of microglia leads to release of various toxic molecules such as superoxide, NO, IL-1β and TNF-α, contributing to neuronal damage in various neurodegenerative disorders [
1].
LX possesses dual anti-inflammatory and pro-resolution activities that have been demonstrated in a multitude of acute and chronic inflammatory conditions [
11]. Previously, LXA
4, ATL and their stable analogues have been shown to play a major role in important functional properties of the central nervous system, such as neural stem cell proliferation and differentiation, pain, and cerebral ischemia [
17‐
19,
33]. In primary murine microglia or N9 microglial cells, expression of ALX2/FPR2 has been identified and is up-regulated by inflammatory stimuli [
20,
21]. In the present study, the expression of ALX2/FPR2 and another murine high-affinity ALX1/FPR-rs1 were confirmed in BV-2 microglial cells. These findings suggest that ATL could work as a modulator of the inflammatory reaction of the brain immune system, eventually acting as a microglial activation repressor.
NO and pro-infiammatory cytokines such as IL-1β and TNF-α are known to be important mediators in the process of infiammation. These proinfiammatory mediators are thought to be responsible for some of the harmful effects of brain injuries and diseases, including ischemia, Alzheimer's disease, Parkinson's disease and multiple sclerosis [
34]. Under various pathological conditions associated with infiammation, large amounts of NO are produced in the brain as a result of the induced expression of iNOS in glial cells [
35]. High levels of NO exert their toxic effects through multiple mechanisms, including lipid peroxidation, mitochondrial damage, protein nitration and oxidation, depletion of antioxidant reserves, activation or inhibition of various signaling pathways, and DNA damage [
35]. Therefore, the effect of ATL on NO production and iNOS expression in LPS-stimulated microglia cells was examined. As shown in previous research [
36,
37], NO is produced at low levels in unstimulated microglia. Stimulation of BV-2 microglial cells with LPS induced strong NO production and iNOS expression. The magnitude of the NO/iNOS response to LPS in BV-2 microglial cells is different in different studies with different concentrations as well as durations of LPS treatment. In the present study, ATL markedly reduced NO production and mRNA and protein expression of iNOS in dose-dependent manners without significant cytotoxicity. This indicates that inhibition of NO production by ATL is a result of inhibition of iNOS gene expression. Previous studies also have shown that LXA
4 and ATL analogues inhibit LPS-induced NO production and peroxynitrite formation in human leukocytes [
38] and in mouse lung [
39].
Pro-infiammatory cytokines produced by activated microglia, including IL-1β and TNF-α, play an important role in the process of neuroinfiammatory diseases [
34]. IL-1β is a potent pro-infiammatory cytokine that acts through IL-1 receptors found on numerous cell types, including neurons and microglia. TNF-α can cause cell death directly by binding to neuronal TNF receptors linked to death domains that activate caspase-dependent apoptosis [
40] or by potentiating glutamate release, thereby enhancing excitotoxicity [
41]. IL-1β and TNF-α also drive self-propagating cycles of microglial activation and neuroinflammation by inducing activation of NF-κB, cytokine generation and further activation of NF-κB. Thus, inhibition of cytokine production or function serves as a key mechanism in the control of neurodegeneration. Our results showed that ATL markedly attenuates the production of IL-1β and TNF-α, and their mRNA expressions; induced by LPS in BV-2 cells. Consistent with our findings, similar results have shown that LXA
4 and ATL inhibit LPS-induced production of IL-1β and TNF-α in uvea and in macrophages and endothelial cells [
42‐
44].
In subsequent studies, we found that ATL has a strong inhibitory effect on infiammatory signaling pathways that include NF-κB and MAPK/AP-1. NF-κB activity increases in acute neurodegenerative disorders such as stroke, severe epileptic seizures, and traumatic brain injury; and in chronic neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, Huntington disease, and amyotrophic lateral sclerosis [
45]. In general, activation of NF-κB in microglia contributes to neuronal injury and promotes the development of neurodegenerative disorders [
45]. NF-κB is known as a pleiotropic regulator of various genes involved in the production of many proinfiammatory cytokines and enzymes. NF-κB is also a central regulator of microglial responses to activating stimuli, including LPS and cytokines [
46]. In this study, ATL was able to inhibit the LPS-evoked degradation of IκB-α, nuclear translocation of NF-κB p65 and the DNA-binding activities of NF-κB in BV-2 cells. Previous studies have shown that LXs reduce nuclear translocation of NF-κB in human neutrophils, mononuclear leukocytes [
38] and macrophages [
43]. It has also been reported that ATLs reduce NF-κB-mediated transcriptional activation in an ALX-dependent manner, and inhibit the degradation of IκB [
47]. Therefore, induction of anti-inflammatory responses by LXs may be dependent on the NF-κB signaling pathway.
In addition, LPS also activates MAPK pathways which lead to the induction of another transcription factor, AP-1. MAPKs are a group of signaling molecules that appear to play key roles in infiammatory processes [
48]. We found that phosphorylation of ERK and p38 MAPK in response to LPS is decreased by ATL treatment. Our results also show that ATL treatment of BV-2 microglia results in decreased DNA-binding activities of AP-1 following LPS stimulation. This observation is in line with studies in mesangial cells, endothelial cells, neutrophils, fibroblasts and T cells, which have shown that ERK and/or p38 MAPK activation is attenuated in the presence of LXs [
42,
49‐
51]. In the present study, ATL failed to inhibit LPS-induced phosphorylation of JNK. A previous study in primary astrocytes found that an ATL analogue prevents ATP-evoked JNK phosphorylation, but has no effect on TNF-α-induced JNK phosphorylation [
33]. Strikingly, our results show that ATL induces JNK phosphorylation, but has no effect on ERK and p38 MAPK activity. In another study, LXA
4 attenuated microvascular fluid leaks caused by LPS partly mediated by the JNK signaling pathway [
52]. LXA
4 and ATL analogues could promote ERK phosphorylation in macrophages and monocytes [
53,
54]. The reasons for these discrepancies are mainly due to differences in experimental models, cell types and stimulators.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YPW, YW and LYL performed the experiments and analyzed the data. JZ, RGL, and JPZ provided useful advice and reviewed the manuscript. YS conceived the study, participated in its design and coordination, and wrote the manuscript. SYY and SLY oversaw the experimental design and edited the manuscript. All authors of this paper have read and approved the final version the manuscript.